KBY Biotech Indexv0.0.34
Search
← Pipeline|MSK-IIT-373

MSK-IIT-373

NDA/BLA
By MSKCC Breast Svc
Source: Trial-derived·Trials: 1
Modality
Radioligand
MOA
KRASG12Ci
Target
ALK
Pathway
Angiogenesis
ALL
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
~Sep 2019
→ ~Dec 2020
Phase 3
~Mar 2021
→ ~Jun 2022
NDA/BLA
Sep 2022
NDA/BLACurrent
NCT08694307
1,411 pts·ALL
2022-09→TBD·Not yet recruiting
1,411 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08694307NDA/BLAALLNot yet recr...1411SeizFreq
Competitors (10)
DrugCompanyPhaseTargetMOA
LisolucimabNovartisApprovedCD20KRASG12Ci
GozelemzoparlimabMerck & CoPhase 2FXIaKRASG12Ci
MRK-8368Merck & CoPhase 3ALKPCSK9i
AZN-8478AstraZenecaNDA/BLASHP2KRASG12Ci
PexazasiranSanofiPreclinicalFXIaKRASG12Ci
TerasacituzumabNovo NordiskNDA/BLAIL-23KRASG12Ci
GSK-6983GSKPhase 2ALKIL-23i
BAY-3308BayerPhase 1ALKSGLT2i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
VRT-6833Vertex PharmaPreclinicalALKVEGFi